Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis

Aamer Sandoo; Theodoros Dimitroulas; Tracey E Toms; James Hodson; Jet J C S Veldhuijzen van Zanten; Jacqueline P Smith; George D Kitas

doi:10.1016/j.clinbiochem.2012.07.092

Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis

Aamer Sandoo, Theodoros Dimitroulas, Tracey E Toms, James Hodson, Jet J C S Veldhuijzen van Zanten, Jacqueline P Smith, George D Kitas

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is characterised by impaired endothelial function which contributes to increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and contributes to endothelial dysfunction. The aim of the present longitudinal study was to investigate the effects of tumour necrosis factor alpha (TNFα) antagonists on serum concentrations of ADMA in RA patients.

Original language	English
Pages (from-to)	1399-403
Number of pages	5
Journal	Clinical Biochemistry
Volume	45
Issue number	16-17
DOIs	https://doi.org/10.1016/j.clinbiochem.2012.07.092
Publication status	Published - Nov 2012

Bibliographical note

Access to Document

10.1016/j.clinbiochem.2012.07.092

Cite this

Sandoo, A., Dimitroulas, T., Toms, T. E., Hodson, J., Veldhuijzen van Zanten, J. J. C. S., Smith, J. P., & Kitas, G. D. (2012). Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. Clinical Biochemistry, 45(16-17), 1399-403. https://doi.org/10.1016/j.clinbiochem.2012.07.092

@article{ac5973fef44a4a688e66738fbd1d23e7,

title = "Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis",

abstract = "Rheumatoid arthritis (RA) is characterised by impaired endothelial function which contributes to increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and contributes to endothelial dysfunction. The aim of the present longitudinal study was to investigate the effects of tumour necrosis factor alpha (TNFα) antagonists on serum concentrations of ADMA in RA patients.",

author = "Aamer Sandoo and Theodoros Dimitroulas and Toms, {Tracey E} and James Hodson and {Veldhuijzen van Zanten}, {Jet J C S} and Smith, {Jacqueline P} and Kitas, {George D}",

year = "2012",

month = nov,

doi = "10.1016/j.clinbiochem.2012.07.092",

language = "English",

volume = "45",

pages = "1399--403",

journal = "Clinical Biochemistry",

issn = "1873-2933",

publisher = "Elsevier",

number = "16-17",

}

Sandoo, A, Dimitroulas, T, Toms, TE, Hodson, J, Veldhuijzen van Zanten, JJCS, Smith, JP & Kitas, GD 2012, 'Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis', Clinical Biochemistry, vol. 45, no. 16-17, pp. 1399-403. https://doi.org/10.1016/j.clinbiochem.2012.07.092

Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. / Sandoo, Aamer; Dimitroulas, Theodoros; Toms, Tracey E et al.
In: Clinical Biochemistry, Vol. 45, No. 16-17, 11.2012, p. 1399-403.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis

AU - Sandoo, Aamer

AU - Dimitroulas, Theodoros

AU - Toms, Tracey E

AU - Hodson, James

AU - Veldhuijzen van Zanten, Jet J C S

AU - Smith, Jacqueline P

AU - Kitas, George D

PY - 2012/11

Y1 - 2012/11

N2 - Rheumatoid arthritis (RA) is characterised by impaired endothelial function which contributes to increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and contributes to endothelial dysfunction. The aim of the present longitudinal study was to investigate the effects of tumour necrosis factor alpha (TNFα) antagonists on serum concentrations of ADMA in RA patients.

AB - Rheumatoid arthritis (RA) is characterised by impaired endothelial function which contributes to increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and contributes to endothelial dysfunction. The aim of the present longitudinal study was to investigate the effects of tumour necrosis factor alpha (TNFα) antagonists on serum concentrations of ADMA in RA patients.

U2 - 10.1016/j.clinbiochem.2012.07.092

DO - 10.1016/j.clinbiochem.2012.07.092

M3 - Article

C2 - 22820438

SN - 1873-2933

VL - 45

SP - 1399

EP - 1403

JO - Clinical Biochemistry

JF - Clinical Biochemistry

IS - 16-17

ER -

Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this